|1.||Choi, Jong Gwon: 1 article (07/2006)|
|2.||Kim, Byung Soo: 1 article (07/2006)|
|3.||Kim, Jun Suk: 1 article (07/2006)|
|4.||Sung, Hwa Jung: 1 article (07/2006)|
|5.||Choi, Chul Won: 1 article (07/2006)|
|6.||Choi, In Keun: 1 article (07/2006)|
|7.||Shin, Sang Won: 1 article (07/2006)|
|8.||Seo, Hee Yun: 1 article (07/2006)|
|9.||Park, Kyong Hwa: 1 article (07/2006)|
|10.||Sul, Hye Ryoung: 1 article (07/2006)|
|1.||Non-Hodgkin Lymphoma (Lymphosarcoma)
11/01/1997 - "Epirubicin (CEOP-Bleo) versus idaurubicin (CIOP-Bleo) in the treatment of elderly patients with aggressive non-Hodgkin's lymphoma: dose escalation studies."
11/01/1997 - "We feel that the CEOP-Bleo regimen with escalated doses of epirubicin is a useful option in the treatment of elderly patients with aggressive non-Hodgkin's lymphoma."
11/01/1997 - "One hundred and sixty nine untreated elderly patients (median age 69 years old; range 60-89 years old) with high or high-intermediate clinical risk non-Hodgkin's lymphoma were enrolled in a controlled clinical trial to evaluate escalated doses of epirubicin in a CEOP-Bleo regimen (cyclophosphamide, vincristine, epirubicin, prednisone and bleomycin), compared to escalated doses of idaurubicin in an CIOP-Bleo regimen (idaurubicin instead of epirubicin). "
07/01/2006 - "The important prognostic factors were evaluated for T-cell non-Hodgkin lymphoma (NHL) patients in a prospective study using the CEOP-B protocol [a modified cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)-like regimen that uses epirubicin instead of doxorubicin with the addition of bleomycin]. "
|2.||Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell)
04/01/1997 - "Dose escalation of epirubicin in the CEOP-BLEO regimen: a controlled clinical trial comparing standard doses for the treatment of diffuse large cell lymphoma."
01/01/2004 - "The intensive CEOP-Bleo regimen with increasing doses of cyclophosphamide and epirubicin is a useful and well-tolerated regimen in the treatment of poor prognosis diffuse large B-cell lymphoma."
04/01/1997 - "One hundred and forty-seven consecutive patients with previously untreated high-intermedium and high clinical risk diffuse large cell lymphoma (DLCL) were included in a prospective clinical trial to evaluate the efficacy and toxicity of escalating doses of epirubicin compared to standard doses in the CEOP-Bleo (cyclophosphamide, epirubicin, vincristine and prednisone and bleomycin) regimen, 55% of the patients were > 60 years old and most patients had adverse prognostic factors at diagnosis. "